Geoffrey Shouse1, Alexey V Danilov1,2, Andy Artz3. 1. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. 2. Leukemia & Lymphoma Society Scholar (#2319-19), New York, NY, USA. 3. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA. aartz@coh.org.
Abstract
PURPOSE OF REVIEW: Validated metrics to optimize older adult patient selection for Chimeric Antigen Receptor T-cell therapy (CART) are lacking; however, some preliminary data suggests that geriatric assessments and cumulative illness rating score may be useful tools. In addition, interventions capable of enhancing outcomes in older adults receiving CART have yet to be elucidated. The purpose of this review is to present data extrapolating from other diseases and therapeutic modalities, related to product selection, toxicity mitigation strategies, comprehensive coordinated models of care, and functional optimization of patients. RECENT FINDINGS: The most robust data in older adults are among relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL) patients where three products are available with the longest clinical follow up and the most abundant real-world evidence (RWE). Data for the approved CART products for follicular lymphoma (FL) and mantle cell lymphoma (MCL) are relatively new and RWE is lacking in general. Data for CART products in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL) are even more recent, but preliminary data in older adults seem to follow the trend of excellent efficacy in this age group with age-stratified toxicity data limited. Landmark trials and RWE studies indicate that the high response rates of CART for older adult patients, age 65 years and older, are maintained, while toxicity may be amplified. Clinically important toxicities include grade 3 or higher cytokine release syndrome (CRS), neurotoxicity, and infections.
PURPOSE OF REVIEW: Validated metrics to optimize older adult patient selection for Chimeric Antigen Receptor T-cell therapy (CART) are lacking; however, some preliminary data suggests that geriatric assessments and cumulative illness rating score may be useful tools. In addition, interventions capable of enhancing outcomes in older adults receiving CART have yet to be elucidated. The purpose of this review is to present data extrapolating from other diseases and therapeutic modalities, related to product selection, toxicity mitigation strategies, comprehensive coordinated models of care, and functional optimization of patients. RECENT FINDINGS: The most robust data in older adults are among relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL) patients where three products are available with the longest clinical follow up and the most abundant real-world evidence (RWE). Data for the approved CART products for follicular lymphoma (FL) and mantle cell lymphoma (MCL) are relatively new and RWE is lacking in general. Data for CART products in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (B-ALL) are even more recent, but preliminary data in older adults seem to follow the trend of excellent efficacy in this age group with age-stratified toxicity data limited. Landmark trials and RWE studies indicate that the high response rates of CART for older adult patients, age 65 years and older, are maintained, while toxicity may be amplified. Clinically important toxicities include grade 3 or higher cytokine release syndrome (CRS), neurotoxicity, and infections.
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Vicki A Morrison; Paul Hamlin; Pierre Soubeyran; Reinhard Stauder; Punit Wadhwa; Matti Aapro; Stuart Lichtman Journal: J Geriatr Oncol Date: 2014-12-07 Impact factor: 3.599
Authors: George W Wright; Da Wei Huang; James D Phelan; Zana A Coulibaly; Sandrine Roulland; Ryan M Young; James Q Wang; Roland Schmitz; Ryan D Morin; Jeffrey Tang; Aixiang Jiang; Aleksander Bagaev; Olga Plotnikova; Nikita Kotlov; Calvin A Johnson; Wyndham H Wilson; David W Scott; Louis M Staudt Journal: Cancer Cell Date: 2020-04-13 Impact factor: 31.743
Authors: Anupama Reddy; Jenny Zhang; Nicholas S Davis; Andrea B Moffitt; Cassandra L Love; Alexander Waldrop; Sirpa Leppa; Annika Pasanen; Leo Meriranta; Marja-Liisa Karjalainen-Lindsberg; Peter Nørgaard; Mette Pedersen; Anne O Gang; Estrid Høgdall; Tayla B Heavican; Waseem Lone; Javeed Iqbal; Qiu Qin; Guojie Li; So Young Kim; Jane Healy; Kristy L Richards; Yuri Fedoriw; Leon Bernal-Mizrachi; Jean L Koff; Ashley D Staton; Christopher R Flowers; Ora Paltiel; Neta Goldschmidt; Maria Calaminici; Andrew Clear; John Gribben; Evelyn Nguyen; Magdalena B Czader; Sarah L Ondrejka; Angela Collie; Eric D Hsi; Eric Tse; Rex K H Au-Yeung; Yok-Lam Kwong; Gopesh Srivastava; William W L Choi; Andrew M Evens; Monika Pilichowska; Manju Sengar; Nishitha Reddy; Shaoying Li; Amy Chadburn; Leo I Gordon; Elaine S Jaffe; Shawn Levy; Rachel Rempel; Tiffany Tzeng; Lanie E Happ; Tushar Dave; Deepthi Rajagopalan; Jyotishka Datta; David B Dunson; Sandeep S Dave Journal: Cell Date: 2017-10-05 Impact factor: 41.582
Authors: Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu Journal: Biol Blood Marrow Transplant Date: 2018-12-25 Impact factor: 5.742
Authors: Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt Journal: N Engl J Med Date: 2018-04-12 Impact factor: 91.245